The evaluation of effectiveness,safety,and economy of imipenem/cilastatin and meropenem in the treatment of urosepsis
Objective To investigate the effectiveness,safety,and economy of imipenem/cilastatin and mero-penem in the treatment of patients with urosepsis.Methods Clinical data of 39 patients with urosepsis received imipenem/cilastatin (n=16)and meropenem (n=23)were collected in our hospital from June 2018 to Decem-ber 2022.Inflammatory markers,platelet,creatinine,clinical efficacy and the occurrence of adverse drug reac-tions (ADRs)were compared between the two groups before and after treatment.Then cost-effectiveness were analyzed.Results The total effective rates were 100％ for both imipenem/cilastatin and meropenem group.In addition to patients who were not responding to treatment,white blood cell count,neutrophil percentage,procal-citonin,and hypersensitive C-reactive protein were lower than before treatment,with statistical significance (P<0.05).However,there was no statistical significance for these indices between the two groups.Comparison of platelet values before and after treatment for both the two groups of patients showed effective therapy.After treat-ment,platelet values were significantly increased compared to before treatment or returned to normal levels (P<0.05).Here was no statistical significance for this index between the two groups.For patients with acute renal failure,the creatinine values after treatment were lower than before or returned to normal levels (P<0.05).The rates of adverse reactions in the two groups were not statistically significant.Cost-effectiveness analysis showed that the cost of meropenem was more expensive than imipenem/cilastatin (P<0.05).Conclusion The effective-ness and safety of imipenem/cilastatin are similar to meropenem.In terms of economy,imipenem/cilastatin is better than meropenem.
万方数据
维普
